Voyager CEO Al Sandrock outlines a focused strategy: remain specialists in neurology, but broaden the therapeutic modalities (gene therapy, proteins, oligonucleotides). This allows them to pursue well-validated CNS targets that are considered "undruggable" by traditional small molecules, which have historically been the only option for crossing the blood-brain barrier.

Yamanaka factors—proteins that can reverse cellular age—are entering their first FDA-approved human clinical trial. The study will deliver the proteins into the eyes of patients to rejuvenate retinal cells and restore vision, marking a milestone for regenerative medicine.

Brief, daily exposure to 670nm red light rejuvenates aging retinal cells by improving mitochondrial function. In studies on individuals over 40, this non-invasive therapy restored age-related visual acuity decline by as much as 22%.

In treating conditions like heart failure, Gordian's approach is not to replace damaged cells but to use gene therapy to "reprogram" existing, dysfunctional ones. This strategy aims to restore the normal function of the patient's own tissue rather than engaging in the more complex task of rebuilding it.

Ophthalmology has become a "safe haven" for gene therapy because it mitigates the field's two main challenges: safety and manufacturing. Localized delivery to the immune-privileged eye improves the safety profile, while the thousand-fold lower required doses simplify manufacturing and dramatically improve the cost of goods.

For intractable diseases like Parkinson's, the IGI takes an 'end-to-end' approach: building better disease models, discovering root causes, and simultaneously exploring multiple treatment modalities like direct CRISPR edits, cell therapies, and microbiome interventions. This tackles the entire problem, not just one piece.

The next frontier for Neuralink is "blindsight," restoring vision by stimulating the brain. The primary design challenge isn't just technical; it's creating a useful visual representation with very few "pixels" of neural stimulation. The problem is akin to designing a legible, life-like image using Atari-level graphics.

Founder Sean Ainsworth intentionally started his pioneering AAV gene therapy in an ocular setting before any Western approvals existed. Because an intravitreal injection uses a very small vector amount, it provided a significant safety advantage and a manageable way to prove the technology before attempting systemic delivery.

The gene therapy field is maturing beyond its initial boom-and-bust cycle. After facing the reality that it isn't a cure-all, the industry is finding stable ground. The future lies not in broad promises but in a focused approach on therapeutic areas where the modality offers a clear, undeniable advantage.